Endobronchial ultrasound for lung cancer diagnosis and staging: a review of the clinical and cost-effectiveness
Ho C, Clark M, Argaez C
Record ID 32011001217
English
Authors' recommendations:
Given the existing evidence, EBUS is an accurate and safe tool in lung cancer diagnosis and staging. The cost-effectiveness of EBUS has not been evaluated, but cost-analyses show that EBUS-TBNA reduced the staging cost by 24% per patient. Using Australian cost-analysis data, and assuming that the costs are similar in Canada, the use of EBUS-TBNA compared to the use of conventional TBNA in Canada for NSCLC staging and the diagnosis of mediastinal masses could lead to estimated savings of C$0.8 million to C$1.3 million per year in the Canadian health care system. The limitation of this cost analysis is that conventional TBNA is not the standard of care for mediastinal staging. There are minimal data on the comparison of EBUS to mediastinoscopy.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/M0011_EBUS_for_Lung_Cancer_L3_e.pdf
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bronchi
- Bronchoscopy
- Lung Neoplasms
- Neoplasm Staging
- Ultrasonography, Interventional
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.